Carlyle agrees to buy Johnson & Johnson unit for $4.15 bln
The Carlyle Group has agreed to acquire Johnson & Johnson's Ortho-Clinical Diagnostics business, which provides solutions for screening, diagnosing, monitoring and confirming diseases, for $4.15 billion. The transaction is subject to regulatory approvals and expected to close mid-2014. Equity for the deal is coming from Carlyle's sixth fund, which closed on $13 billion in November. The firm lined up financing for the deal from Barclays, Goldman Sachs, Credit Suisse, UBS and Nomura.






